A necdotal evidence from clinicians in Germany suggests an increase in scabies; sales of scabicides by pharmacies in Germany have quadrupled during 2012-2017 (1,2). In addition, clinicians and scientists have raised concerns about resistance to standard treatment (3). In Germany, scabies is not reportable, and no recent national incidence estimates exist.Scabies is diagnosed clinically, but confi rmation through skin scrapings or dermatoscopy is not always performed in Germany (1). The national guideline recommends a single application of permethrin 5% cream for common scabies (4). Ivermectin, licensed in Germany in 2016, is recommended in cases of crusted scabies, immunosuppression, and contraindications for topical treatment (4). A second application is recommended after 7-15 days in outbreaks and patients with crusted scabies, immunosuppression, or persistent infestation. We investigated incidence of scabies in Germany for 2009-2018.
The StudyWe analyzed claims data of outpatients insured by German statutory health insurance (SHI) funds, which applies to ≈90% of the population of Germany (5). Information on all ambulatory consultations and fi lled prescriptions of SHI-covered patients are gathered and stored up to 10 years for the SHI Physicians' Association by the Central Research Institute of Ambulatory Health Care.We defi ned a case as any patient consultation during 2009-2018 marked with code B86, "scabies," from the International Classifi cation of Diseases (ICD), 10th Revision. We counted patients with repeat consultations only once per year. We excluded cases with missing or implausible age or sex information. We extracted, aggregated, and analyzed time of diagnosis, age, sex, and area of residence. We calculated incidence as number of cases per 100,000 SHI members per year. We also analyzed prescribing data for allethrin, benzyl benzoate, crotamiton, ivermectin, lindane, and permethrin linked to cases. We assumed treatment failure and defi ned repeated prescriptions if a patient received prescriptions for 2 scabicides within a year >28 days apart, regardless of substance (6). Use of claims data is regulated by the Code of Social Law (Sozialgesetzbuch) in Germany; ethics approval and informed consent are not required.In 2009, German SHI funds had 70,011,508 members, and scabies was diagnosed 42,585 times in physician practices, out-of-hours services, and hospital emergency departments in the ambulatory setting. In 2018, diagnoses were 382,043 for 72,802,098 members, a 9-fold increase in 9 years (Figure 1) and an overall incidence of 525/100,000 persons.The highest incidence and a >11-fold increase during 2009-2018 were observed in persons 15-19 and 20-24 years of age (Figure 2). The increase in incidence was more pronounced in boys and men, especially for those 15-19 (23% lower incidence than girls and women in 2009 vs. 7% higher in 2018) and 20-24 years of age (5% lower incidence in 2009